Skip to content
Precision for Medicine
Contact Us
Upcoming Webinar

Beyond the Data Deluge: Immune profiling in early immuno-oncology trials

Register now
iStock-1421515036 (2) iStock-1421515036 (2)

Gene Expression Profiling of Biopsies

Gene expression profiling of tumor biopsies and liquid biopsies can provide insight into inflammation and overall immune status
Profiling of biopsies by gene expression can serve as a tool for screening tumors that may respond to treatments such as checkpoint inhibitors, for evaluating therapeutic efficacy, for illuminating mechanism of action, and for a range of other applications

Comprehensive and quantitative gene expression profiling

Precision offers gene expression profiling and transcriptomics assays to monitor immune status using next generation sequencing (NGS), NanoString, qPCR, and Droplet Digital™ PCR (ddPCR) technologies. For sample types and needs other than immune profiling of biopsies, Precision also offers a full suite of genomics applications.

Our services are designed to meet your project objectives, whether through pre-existing panels or a customized assay.

Illumina and Thermo Fisher NGS Sequencers

We use both Illumina and Thermo Fisher for next-gen sequencing. Also, RNA-seq studies are done using Illumina, including the AmpliSeq for Illumina Immune Response Panel.

NanoString nCounter®

For highly multiplexed, quantitative gene expression studies, we use the NanoString nCounter® platform. This system directly detects RNA, avoiding the potential for introduced bias with approaches that rely on PCR-based amplification.

We can use NanoString’s immuno-oncology and immunology panels or create a custom panel for your study.

QuantStudio™ 12K flex real-time PCR system

For cost-effective, multiplexed gene expression profiling of many samples in parallel, we offer analyses using OpenArray plates on the QuantStudio 12K Flex qPCR platform.

QX200™ ddPCR™

Digital PCR is appropriate when highly sensitive analyses and absolute quantification is needed. Precision utilizes the Bio-Rad QX200 ddPCR System.

Agena MassARRAY®

High-throughput solution for genotyping, somatic mutation detection, DNA methylation analysis, and gene expression regulation analysis. Precision for Medicine offers MassARRAY® assays either as an individual service or as part of a comprehensive therapeutic development package, which includes biomarker assays and clinical trials.

Precision also provides research-ready biospecimens

In addition to services, Precision has biospecimens ready for genomic analysis, as well as specimens pre-characterized via NGS.

FFPE Tissues Explore NGS Characterized Biospecimens Explore Tissue Microarrays Explore

Explore the Precision blog

Read our blog to gain more insights and discover work that Precision has supported.

Explore our blog
Read: From Bench to Breakthrough: How Custom Kitting Fuels Precision Trials From Bench to Breakthrough: How Custom Kitting Fuels Precision Trials

Translational Research - Biomarkers

From Bench to Breakthrough: How Custom Kitting Fuels Precision Trials

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778875, hs_child_table_id=0, hs_updated_at=1716454216458, hs_published_at=1748379090824, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475007, name='Precision for Medicine Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1716212769184, hs_created_at=1709645745106, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job= Chief Scientific Officer, slug=deborah-phippard, email=, hs_updated_by_user_id=51739740}, second={hs_id=182710436924, hs_child_table_id=0, hs_updated_at=1731419754428, hs_published_at=1748379090824, description=Christie Bongel, MS, CT(ASCP), brings nearly two decades of experience in both research and clinical medicine. As the site director for Precision for Medicine’s IHC Center of Excellence in North Carolina, she excels in managing scientific operations and collaborating with clients. Christie is skilled in cytology, laboratory medicine, and molecular diagnostics. Her role focuses on building an energized team dedicated to delivering life-changing outcomes for patients. Christie earned her MS in Applied Biotechnology and is an ASCP certified cytotechnologist., avatar=Image{width=260,height=260,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Christie%20Bongel_Square_260px.jpg',altText='Christie Bongel_Square_260px',fileId=178044303113}, lastname= Bongel, hs_initial_published_at=1731517828480, hs_created_by_user_id=28386183, hs_created_at=1731419696820, hs_is_edited=false, hs_deleted_at=0, name=Christie, job=Site Director - Histology, slug=christie-bongel, hs_updated_by_user_id=51739740}, third={}})
  • Deborah P. avatar

    Deborah P.
  • Christie . avatar

    Christie .
Discover
Read: Global Phase 1–2 ROS1 Inhibitor Case Study in NSCLC: Precision’s Path to Zero Data Issues Across 60+ Sites Global Phase 1–2 ROS1 Inhibitor Case Study in NSCLC: Precision’s Path to Zero Data Issues Across 60+ Sites

Clinical Trials - Oncology - Rare Diseases

Global Phase 1–2 ROS1 Inhibitor Case Study in NSCLC: Precision’s Path to Zero Data Issues Across 60+ Sites

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1716454310949, hs_published_at=1748379090824, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins-White-150x150.jpeg',altText='Alexis-Hobbins-White-150x150',fileId=164710912635}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White
Discover
Read: Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss

Clinical Trials - Oncology - Cell Therapies

Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1716454310949, hs_published_at=1748379090824, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins-White-150x150.jpeg',altText='Alexis-Hobbins-White-150x150',fileId=164710912635}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White
Discover